← Back to Search

LY3871801 (Part B) for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 up to postdose on day 17

Summary

This trial tests a new drug, LY3871801, to see if it is safe and well-tolerated when taken multiple times. It includes healthy participants from both Asian and Non-Asian backgrounds. Researchers will measure how much of the drug enters the bloodstream and how long it remains in the body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 up to postdose on day 17
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 up to postdose on day 17 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3871801
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3871801

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3871801 (Part B)Experimental Treatment1 Intervention
LY3871801 administered orally in Chinese Participants.
Group II: LY3871801 (Part A)Experimental Treatment1 Intervention
LY3871801 administered orally in Japanese and Non-Asian Participants.
Group III: Placebo (Part B)Placebo Group1 Intervention
Placebo administered orally in Chinese Participants.
Group IV: Placebo (Part A)Placebo Group1 Intervention
Placebo administered orally in Japanese and Non-Asian Participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3871801
2022
Completed Phase 1
~90

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,667 Previous Clinical Trials
3,228,445 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,383 Previous Clinical Trials
426,109 Total Patients Enrolled

Media Library

LY3871801 (Part B) Clinical Trial Eligibility Overview. Trial Name: NCT05960851 — Phase 1
~14 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top